Vadodara-based Genexis Biotech raises Rs 4 crore in a seed funding round

Genexis Biotech, a bio-manufacturing startup focused on developing animal-origin-free recombinant proteins using recombinant technology and precision fermentation, has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. 

The startup plans to use the capital to scale its bioreactor capacity, develop downstream processing infrastructure, and launch a suite of smart proteins and recombinant enzymes. It will also focus on strengthening quality control, regulatory compliance, and expanding sales and distribution channels.

Founded in 2019 by Vipul Kumar and Jitendra Wagh, Genexis Biotech operates a certified Class 10,000 facility and is in the process of setting up a Good Manufacturing Practice-compliant unit, as part of its push toward entering the regulated biotech export market.

“At Genexis Biotech, we are building India’s deeptech backbone for animal-origin-free protein production,” said Kumar. “The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food, and bio-industrial sectors.”

“Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale,” said Mihir Joshi, Managing Director of GVFL. “Its R&D strength, infrastructure, and early traction position it well to serve growing demand across biopharma, food-tech, and life sciences.”

Genexis has formed partnerships with pharmaceutical companies, biotech startups, and academic laboratories. In 2023, the startup signed an MoU with the Gujarat government to scale recombinant protein manufacturing and showcased its capabilities at the Global Bio‑India 2024.

It also plans to develop encapsulated growth factor formulations for cosmetic applications and to collaborate with contract development and manufacturing organisations (CDMOs).

GVFL, based in Ahmedabad, is one of India’s earliest venture capital firms, has backed over 100 companies with dozens of exits. Its investment thesis spans healthtech, fintech, clean tech, and enterprise solutions, with a growing focus on deeptech and biotech innovations.